Retrospective evaluation of various weight descriptors and formulas for dose calculation of carboplatin in obese patients;Dosisberechnung von carboplatin bei übergewicht: Retrospektive evaluierung verschiedener gewichtsdeskriptoren und formeln

Krankenhauspharmazie

Volumn 33, Issue 1, 2012, Pages 2-10

  Kaag, Dieter ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Carboplatin; Cock croft Gault; Dose calculation; Glomerular filtration rate; Obesity

Indexed keywords

CARBOPLATIN;

ADULT; AREA UNDER THE CURVE; BODY MASS; BODY WEIGHT; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG CLEARANCE; DRUG URINE LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OBESITY; RETROSPECTIVE STUDY; REVIEW; URINALYSIS;

EID: 84856023499     PISSN: 01737597     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Mathijssen RHJ, de Jong FA, Loos WJ, van der Bool JM, et al. Flat-fixed dosing versus body surface area-based dosing of anticancer drugs in adults: Does it make a difference? Oncologist 2007;12:913-23. (Pubitemid 47359133)
2. Albert DS, Dorr RT. New perspectives on an old friend: Optimizing carboplatin for the treatment of solid tumors. Oncologist 1998;3:15-34. (Pubitemid 28106719)
3. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, et al. Carboplatin dosage. Prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-56. (Pubitemid 19272848)
4. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
5. Coresh J, Astor BC, McQuillan G, Kusek J, et al. Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis 2002;39:920-9. (Pubitemid 34454210)
6. Léger F, Séronie-Vivien S, Makdessi J, Lochon I, et al. Impact of the biochemical assay for serum creatinine measurement on the individual carboplatin dosing: A prospective study. Eur J Cancer 2002;38:52-6. (Pubitemid 34031825)
7. Levey AS, Coresh J, Greene T, Marsh J, et al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007;53:766-72. (Pubitemid 46580250)
8. 99mDTPA clearance) in cancer patients. Ann Oncol 2002;13:949-55.
9. Dooley MJ, Singh S, Rischin D. Rounding of low serum creatinine levels and consequent impact on accuracy of bedside estimates of renal function in cancer patients. Br J Cancer 2004;90:991-5. (Pubitemid 38495817)
10. Herrington JD, Tran HT, Riggs MW. Prospective evaluation of carboplatin AUC dosing in patients with a BMI ≥ 27 or cachexia. Cancer Chemother Pharmacol 2006;57:241-7. (Pubitemid 41779844)
11. Kaag D, Steins M. Impact of rounding low serum creatinine concentrations on the accuracy of carboplatin AUC dosing. Eur J Hosp Pharm Sci 2011;17:13-20.
12. Salazar DE, Corcoran GB. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med 1988;84:1053-60.
13. Bénézet S, Guimbaud R, Chatelut E, Chevreau C, et al. How to predict carboplatin clearance from standard morphological and biological characteristics in obese patients. Ann Oncol 1997;8:607-9. (Pubitemid 127746495)
14. Schmitt A, Gladieff L, Lansiaux A, Bobin-Dubigeon C, et al. A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients. Clin Cancer Res 2009;15:3633-9.
15. Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 2004;58:119-33. (Pubitemid 39043992)
16. Cheymol G. Effects of obesity on pharmacokinetics. Clin Pharmacokinet 2000;39:215-31.
17. Janmahasatian S, Duffull SB, Ash S, Ward LC, et al. Quantification of lean body weight. Clin Pharmacokinet 2005;44:1051-65.
18. Duffull SB, Dooley MJ, Green B, Poole SG, et al. A standard weight descriptor for dose adjustment in the obese patient. Clin Pharmacokinet 2004;43:1167-78. (Pubitemid 40013182)
19. Wright JG, Boddy AV, Highley M, Fenwick J, et al. Estimation of glomerular filtration rate in cancer patients. Br J Cancer 2001;84:452-9. (Pubitemid 32215868)
20. Levey AS, Coresh J, Greene T, Stevens LA, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-54. (Pubitemid 46768608)
21. Levey AS, Stevens LA, Schmid CH, Zhang YL, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-12.
22. Horio M, Imai E, Yasuda Y, Watanabe T, et al. Modification of the CKD Epidemiology Collaboration (CKD-EPI) equation for Japanese: Accuracy and use for population estimates. Am J Kidney Dis 2010;56:32-8.
23. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function - measured and estimated glomerular filtration rate. NEJM 2006;354:2473-83. (Pubitemid 43855050)
24. Bearden DT, Rodvold KA. Dosage adjustments for antibacterials in obese patients. Applying clinical pharmacokinetics. Clin Pharmacokinet 2000;38:415-26. (Pubitemid 30265261)
25. Sparreboom A, Wolff AC, Mathijssen RHJ, Chatelut E, et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 2007;25:4707-13. (Pubitemid 350086471)
26. Ekhart C, Rodenhuis S, Schellens JHM, Beijnen JH, et al. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter? Cancer Chemother Pharmacol 2009;64:115-22.
27. De Jonge ME, Mathot RAA, van Dam SM, Beijnen JH, et al. Extremely high exposure in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin. Cancer Chemother Pharmacol 2002;50:251-5. (Pubitemid 35013664)
28. Demirovic JA, Barton Pai A, Pai MP. Estimation of creatinine clearance in morbidly obese patients. Am J Health Syst Pharm 2009;66:642-8.
29. Han PY, Duffull SB, Kirkpatrick CMJ, Green B. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther 2007;82:505-8. (Pubitemid 47622534)
30. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010;49:71-87.
31. Chatelut E, Canal P, Brunner V, Chevreau C, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1995;87:573-80.
32. Ando M, Minami H, Ando Y, Saka H, et al. Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level. Clin Cancer Res 2000;6:4733-8. (Pubitemid 32110412)
33. Okamoto H, Nagatomo A, Kunitoh H, Kunikane H, et al. Prediction of carboplatin clearance calculated by patient characteristics of 24-h-creatinine clearance: a comparison of the performance of three formulae. Cancer Chemother Pharmacol 1998;42:307-12. (Pubitemid 28393848)
34. Dooley MJ, Poole SG, Rischin D, Webster LK. Carboplatin dosing: gender bias and inaccurate estimates of glomerular filtration rate. Eur J Cancer 2002;38:44-51. (Pubitemid 34031824)
35. Van Warmerdam LJC, Rodenhuis S, ten Bokkel Huinink WW, Maes RAA, et al. Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin. Cancer Chemother Pharmacol 1996;37:266-70.
36. Verhave JC, Baljé-Volkers CP, Hillege HL, de Zeeuw D, et al. The reliability of different formulae to predict creatinine clearance. J Intern Med 2003;253:563-73. (Pubitemid 36543296)
37. Holweger K, Lipp HP, Dietz K, Hartmann JT, et al. Novel algorithm for more accurate calculation of renal function in adults with cancer. Ann Pharmacother 2008;42:1749-57.
38. Holweger K, Lipp HP, Beijnen JH, Bokemeyer C, et al. Evaluation of a non-cystatin-C-based novel algorithm to calculate individual glomerular filtration rate in cancer patients receiving carboplatin. Cancer Chemother Pharmacol 2011;68:693-701.
39. Sèronie-Vivien S, Toullec S, Malard L, Thomas F, et al. Contribution of the MDRD equation and cystatin C for renal function estimates in cancer patients. Med Oncol 2006;23:63-73. (Pubitemid 43787119)
40. Shord SS, Bressler LR, Radhakrishnan L, Chen N, et al. Evaluation of the modified diet in renal disease equation for calculation of carboplatin dose. Ann Pharmacother 2009;43:235-41.
41. De Lemos ML, Hsieh T, Hamata L, Levin A, et al. Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies. Gynecol Oncol 2006;103:1063-9. (Pubitemid 44821334)
42. Poole SG, Dooley MJ, Rischin D. Calculating carboplatin doses using the 4-variable modification of diet in renal disease (4-v MDRD) estimate of glomerular filtration rate (GFR) in the Calvert formula (abstract 2521). 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 2007;25(Suppl):2521.
43. Cirillo M, Anastasio P, de Santo NG. Relationship of gender, age, and body mass index to errors in predicted kidney function. Nephrol Dial Transplant 2005;20:1791-8. (Pubitemid 41222590)
44. Verhave JC, Fesler P, Ribstein J, du Cailar G, et al. Estimation of renal function in subjects with normal serum creatinine levels: influence of age and body mass index. Am J Kidney Dis 2005;46:233-41. (Pubitemid 41040351)
45. Michels WM, Grootendorst DC, Verduijn M, Elliott EG, et al. Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol 2010;5:1003-9.
46. Froissart M, Rossert J, Jacquot C, Paillard M, et al. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol 2005;16:763-73. (Pubitemid 41725113)
47. 2. Am J Kidney Dis 2010;56:486-95.
48. Redal-Baigorri B, Stokholm KH, Rasmussen K, Jeppesen N. Estimation of kidney function in cancer patients. Dan Med Bull 2011;58:A4236.
49. Stevens LA, Schmid CH, Zhang YL, Coresh J, et al. Development and validation of GFR-estimating equations using diabetes, transplant and weight. Nephrol Dial Transplant 2010;25:449-57.
50. Dooley MJ, Poole SG, Rischin D. Comparison of bedside estimates of renal function and measured glomerular filtration rate (GFR) in 510 adult oncology patients (abstract 19512). 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 2007;25(Suppl):19512.
51. Traynor J, Mactier R, Geddes CC, Fox JG. How to measure renal function in clinical practice. BMJ 2006;333:733-7. (Pubitemid 44555171)